Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2016', provides an overview of the Herpes Labialis (Oral Herpes) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Herpes Labialis (Oral Herpes), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Herpes Labialis (Oral Herpes) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Herpes Labialis (Oral Herpes) - The report reviews pipeline therapeutics for Herpes Labialis (Oral Herpes) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Herpes Labialis (Oral Herpes) therapeutics and enlists all their major and minor projects - The report assesses Herpes Labialis (Oral Herpes) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Herpes Labialis (Oral Herpes) Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Herpes Labialis (Oral Herpes) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Herpes Labialis (Oral Herpes) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Herpes Labialis (Oral Herpes) Overview 7 Therapeutics Development 8 Pipeline Products for Herpes Labialis (Oral Herpes) - Overview 8 Pipeline Products for Herpes Labialis (Oral Herpes) - Comparative Analysis 9 Herpes Labialis (Oral Herpes) - Therapeutics under Development by Companies 10 Herpes Labialis (Oral Herpes) - Therapeutics under Investigation by Universities/Institutes 11 Herpes Labialis (Oral Herpes) - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Herpes Labialis (Oral Herpes) - Products under Development by Companies 15 Herpes Labialis (Oral Herpes) - Products under Investigation by Universities/Institutes 16 Herpes Labialis (Oral Herpes) - Companies Involved in Therapeutics Development 17 Beech Tree Labs, Inc. 17 Foamix Pharmaceuticals Ltd. 18 Mymetics Corporation 19 NanoViricides, Inc. 20 Onxeo SA 21 Shulov Innovative Science Ltd. 22 TGV-Laboratories 23 Vironova AB 24 Herpes Labialis (Oral Herpes) - Therapeutics Assessment 25 Assessment by Monotherapy Products 25 Assessment by Target 26 Assessment by Mechanism of Action 28 Assessment by Route of Administration 30 Assessment by Molecule Type 32 Drug Profiles 34 acyclovir - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 acyclovir - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Aspidasept - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 B-220 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 BTL-TMLHSV - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 herpes simplex virus [type 1, 2] vaccine - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 herpes simplex virus [type 1, 2] vaccine - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Small molecule for Cold Sores - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Teg-379 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 ZEP-3 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Herpes Labialis (Oral Herpes) - Recent Pipeline Updates 45 Herpes Labialis (Oral Herpes) - Dormant Projects 48 Herpes Labialis (Oral Herpes) - Discontinued Products 49 Herpes Labialis (Oral Herpes) - Product Development Milestones 50 Featured News & Press Releases 50 Feb 16, 2016: Cipher Pharmaceuticals announces Sitavig accepted for review by Health Canada 50 Jul 21, 2014: BioAlliance Pharma announces the launch of Sitavig in the United States by its partner Innocutis and the granting of a new U.S. Sitavig patent 50 Jul 10, 2013: BioAlliance Pharma expands and strengthens its industrial property assets with two patent grants 51 May 27, 2013: BioAlliance Pharma Presents Results Of Sitavig At 10th EADV Symposium 51 Apr 15, 2013: BioAlliance Pharma's Sitavig Receives US Marketing Authorization For Treatment Of Herpes Labialis 52 Apr 04, 2013: Beech Tree Labs Successfully Completes IND Phase I/IIa Oral Herpes Clinical Trial 53 Jul 26, 2012: BioAlliance Pharma Receives US Patent Covering Sitavig 53 May 29, 2012: BioAlliance Announces Receivability Of Sitavig US Registration Dossier 53 Oct 05, 2011: BioAlliance Submits Sitavir European Registration Dossier Through European Decentralized Procedure 54 Feb 07, 2011: BioAlliance Pharma Presents Results Of International Survey Performed With Nielsen In Patients Suffering From Herpes Labialis 54 Appendix 56 Methodology 56 Coverage 56 Secondary Research 56 Primary Research 56 Expert Panel Validation 56 Contact Us 56 Disclaimer 57
List of Tables
Number of Products under Development for Herpes Labialis (Oral Herpes), H1 2016 8 Number of Products under Development for Herpes Labialis (Oral Herpes) - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Late Stage Development, H1 2016 12 Comparative Analysis by Clinical Stage Development, H1 2016 13 Comparative Analysis by Early Stage Development, H1 2016 14 Products under Development by Companies, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Herpes Labialis (Oral Herpes) - Pipeline by Beech Tree Labs, Inc., H1 2016 17 Herpes Labialis (Oral Herpes) - Pipeline by Foamix Pharmaceuticals Ltd., H1 2016 18 Herpes Labialis (Oral Herpes) - Pipeline by Mymetics Corporation, H1 2016 19 Herpes Labialis (Oral Herpes) - Pipeline by NanoViricides, Inc., H1 2016 20 Herpes Labialis (Oral Herpes) - Pipeline by Onxeo SA, H1 2016 21 Herpes Labialis (Oral Herpes) - Pipeline by Shulov Innovative Science Ltd., H1 2016 22 Herpes Labialis (Oral Herpes) - Pipeline by TGV-Laboratories, H1 2016 23 Herpes Labialis (Oral Herpes) - Pipeline by Vironova AB, H1 2016 24 Assessment by Monotherapy Products, H1 2016 25 Number of Products by Stage and Target, H1 2016 27 Number of Products by Stage and Mechanism of Action, H1 2016 29 Number of Products by Stage and Route of Administration, H1 2016 31 Number of Products by Stage and Molecule Type, H1 2016 33 Herpes Labialis (Oral Herpes) Therapeutics - Recent Pipeline Updates, H1 2016 45 Herpes Labialis (Oral Herpes) - Dormant Projects, H1 2016 48 Herpes Labialis (Oral Herpes) - Discontinued Products, H1 2016 49
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.